# UK Gene Therapy Market

> UK Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Applications (Research, Clinical, Commercial) and By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 19.04%
- **2024:** $ 306 Million
- **2025:** $ 364.26 Million
- **2035:** $ 2,082 Million
- **Key Players:** Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB)

**Report ID:** MRFR/Pharma/51497-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/uk-gene-therapy-market-53258

---

## Market Summary

## **UK Gene Therapy Market Overview**

As per MRFR analysis, the UK Gene Therapy Market Size was estimated at 322.5 (USD Million) in 2024.The UK Gene Therapy Market Industry is expected to grow from 363.5(USD Million) in 2025 to 1,820 (USD Million) by 2035. The UK Gene Therapy Market CAGR (growth rate) is expected to be around 15.77% during the forecast period (2025 - 2035)

**Key UK Gene Therapy Market Trends Highlighted**

The UK Gene Therapy Market is experiencing several significant trends that highlight its dynamic nature. One key market driver is the increasing prevalence of genetic disorders and chronic diseases, which has led to a higher demand for innovative treatment options. The UK government’s commitment to advancing healthcare technology, along with substantial funding for research and development, is propelling the growth of gene therapies. Furthermore, partnerships between UK biotech firms and global pharmaceutical companies are fostering innovation and enhancing the availability of gene therapies. 

Recently, there has been a notable shift towards personalized medicine within the UK.Tailoring treatments based on individual genetic profiles is becoming more prevalent, as it offers the potential for more effective therapies. This trend is supported by advancements in genetic testing technologies that allow for more precise patient selection, ultimately driving the adoption of gene therapies. The regulatory environment in the UK has also adapted to be more accommodating, with streamlined approval processes for innovative therapies.

This encourages companies to invest in gene therapy development, reflecting an overall trend towards faster and more efficient product launches. Opportunities for growth in the UK Gene Therapy Market can be explored by focusing on rare diseases, where gene therapies can provide significant benefits.The government's initiatives to support healthcare innovations, including funding for clinical trials, open avenues for companies to bring their therapies to market. Additionally, collaboration between academic institutions and industry players is expected to lead to breakthroughs in gene therapy research, enhancing the UK’s position as a leader in this field. 

As the UK prioritizes biotechnology and genomic research, the landscape for gene therapies continues to evolve, presenting various chances for players in this market to expand their reach and impact.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**UK Gene Therapy Market Drivers**

**Rising Incidence of Genetic Disorders**

The increasing prevalence of genetic disorders in the UK is driving the growth of the UK Gene Therapy Market Industry. According to the National Health Service (NHS), approximately 1 in 2,500 babies is born with a rare genetic disorder. This statistic highlights a significant patient population that could benefit from gene therapy treatments. Organizations such as the NHS and Genomics England are actively involved in initiatives to enhance genetic screening and therapy development, contributing to the increasing demand for innovative treatments in the UK.

The increasing awareness of genetic disorders and advocacy efforts, along with the company Autolus Therapeutics initiating stronger Research and Development (R&D) activities, all further reinforce the potential development of the UK Gene Therapy Market Industry.

**Advancements in Gene Delivery Systems**

Technological advancements in gene delivery systems have significantly improved the efficacy of gene therapies in the UK. Innovations such as viral vectors and nanoparticle technologies are making gene therapies safer and more effective. The UK government has invested in various biotech innovation programs, incentivizing developments in gene therapy techniques. For instance, the UK Research and Innovation (UKRI) has funded projects focused on advanced drug delivery methods, which have shown promise in delivering therapeutic genes more efficiently.

This development resonates with increasing pharmaceutical interest and investment in gene therapies, positioning the UK as a leader in the Gene Therapy Market Industry.

**Growing Investments from Pharmaceutical Companies**

The UK Gene Therapy Market Industry is witnessing substantial investments from major pharmaceutical companies, which are crucial for furthering R&D. For example, within the last five years, leading firms like GSK and AstraZeneca have significantly increased their focus on gene therapies through acquisitions and internal development initiatives. The UK government’s favorable policies, such as tax incentives for R&D, have propelled these investments, resulting in approximately 2 billion being allocated to genetic research initiatives in the past year alone.

Such capital influx enhances innovation and brings forward the development of advanced therapies, strengthening the UK’s position in the global gene therapy landscape.

**UK Gene Therapy Market Segment Insights**

**Gene Therapy Market Therapeutic Area Insights**

The UK Gene Therapy Market, particularly within the Therapeutic Area segment, demonstrates a promising trajectory driven by advancements in biotechnology and an increasing need for effective treatment options. This market has observed significant dynamics due to the rising prevalence of chronic diseases and genetic disorders, alongside the growing recognition of gene therapy's potential to address these challenges. Oncology remains a crucial focus area, fueled by a high demand for innovative cancer treatments, with gene therapies offering new hope for patients who have exhausted other options.

Genetic disorders are also pivotal, as genetic modifications hold the potential to correct rare inherited conditions, thereby improving patient quality of life and reducing long-term healthcare costs. Furthermore, infectious diseases are gaining attention in the context of gene therapy, particularly in vaccine development and therapeutics, especially highlighted during recent global health challenges. The cardiovascular disease segment is increasingly leveraging gene therapy to tackle complex conditions, including heart failure, thereby pushing the boundaries of traditional treatments.

Neurological disorders represent another vital area of growth, nascent with therapeutic interventions aimed at conditions like Alzheimer’s disease and Parkinson’s disease, which affect a significant portion of the UK's aging population. Each of these categories contributes to the diversification and expansion of the UK Gene Therapy Market, highlighting the country's commitment to harnessing innovative treatments that can transform patient outcomes. The intersection of these therapeutic areas reflects not only the medical needs within the UK but also aligns with the government's push toward investing in innovative healthcare solutions as part of the long-term health strategy.

The implication of government initiatives aimed at facilitating Research and Development is evident, providing a supportive framework for the commercialization of gene therapies across various disease categories, allowing the UK to position itself as a leader in this burgeoning field. The overall segmentation of the UK Gene Therapy Market, grounded in its Therapeutic Area, underscores not only the growth potential but also the necessity for sustained investment and regulatory support to navigate challenges that include patient access, ethical considerations, and market adoption for these advanced therapies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Gene Therapy Market Technology Insights**

The Technology segment of the UK Gene Therapy Market encompasses various innovative approaches that drive advancements in treating genetic disorders. Viral Vectors have gained prominence due to their efficiency in delivering therapeutic genes, making them a critical tool in Gene Therapy applications. CRISPR technology has revolutionized the field by providing accurate and efficient gene editing capabilities, propelling research and therapeutic developments.

Gene Editing continues to be a focal area as it allows for precise alterations in the genome, facilitating the treatment of a wide range of genetic conditions.RNA Therapy emerged as a powerful method for modulating gene expression, showing significant potential in treating diseases at the molecular level. 

Non-viral methods are also gaining traction, offering safer alternatives to gene delivery without the associated risks of viral vectors. These diverse technology approaches not only highlight the innovative methodologies being deployed within the UK Gene Therapy Market but also underscore the opportunities for enhancing treatment efficacy and patient outcomes in genetic therapies. Overall, the Technology segment is integral for driving the growth and future success of Gene Therapy in the UK, empowering advancements in the field and addressing unmet medical needs.

**Gene Therapy Market Application Insights**

The UK Gene Therapy Market is characterized by its diverse Application segment, which plays a crucial role in both the therapeutic landscape and advancements in medical science. This segment is predominantly divided into Research, Clinical, and Commercial applications, each serving specific purposes. Research applications are pivotal in driving innovations and facilitating the development of new therapies, showcasing significant activities in universities and biotechnology firms. Clinical applications focus on the translation of these innovations into effective treatments for various genetic disorders, emphasizing the importance of safety and efficacy in patient outcomes.

Meanwhile, Commercial applications highlight the industry's efforts to bring these therapies to market, addressing the growing demand for personalized medicine. The market dynamics reflect a strong emphasis on patient-centric solutions and are bolstered by favorable governmental policies aimed at encouraging research and development initiatives. With ongoing advancements in technology and a robust healthcare infrastructure in the UK, the Application segment of the UK Gene Therapy Market is well-positioned for substantial growth, offering numerous opportunities for stakeholders across all levels of the industry.

This focus on applications reinforces the significance of gene therapy as a transformative approach to treatment, paving the way for the future of medicine in the UK.

**Gene Therapy Market Route of Administration Insights**

The Route of Administration segment within the UK Gene Therapy Market plays a crucial role in the efficient delivery of therapeutic agents to patients, addressing diverse medical conditions. The market encompasses various methods, including Intravenous, Intramuscular, Intradermal, Intrathecal, and Oral administration. Among these, Intravenous delivery holds significant importance, often chosen for its rapid onset of action and ability to deliver large volumes, making it suitable for complex therapies. Intramuscular administration is another vital route, particularly valued for its ease of use and provisions for self-administration, enhancing patient compliance.

Intradermal and Intrathecal methods are critical for targeting localized conditions and central nervous system disorders, respectively, which are prevalent in the UK healthcare landscape. Oral administration, while less common in gene therapy, represents an emerging frontier, providing a non-invasive delivery option that could improve accessibility for patients.

As the UK Gene Therapy Market continues to expand, advancements in administration techniques may overcome existing challenges, driving market growth and offering new therapeutic opportunities.With a robust investment in Research and Development, the UK aims to remain at the forefront of innovative gene therapies, further solidifying the significance of the Route of Administration segment.

**UK Gene Therapy Market Key Players and Competitive Insights**

The UK Gene Therapy Market is witnessing transformative growth driven by advancements in biotechnology and an increasing focus on personalized medicine. This sector is characterized by intense competition among a range of players, from established pharmaceutical giants to emerging biotech firms. The landscape is notably shaped by regulatory frameworks, funding opportunities, and the demand for innovative treatments targeting rare and complex genetic disorders. As the market evolves, companies are continuously striving to enhance their product pipelines, engage in strategic collaborations, and leverage cutting-edge technologies to maintain a competitive edge. 

The competitive insights highlight the strategic positioning of organizations, revealing key trends and areas of investment that could define the future of gene therapy in the UK.Finite Resources has been making strides within the UK Gene Therapy Market, capitalizing on its streamlined operations and innovative approach to genetic treatments. The company leverages its expertise in gene delivery systems and has established strong alliances with research institutions and healthcare providers, bolstering its market presence. This strategic positioning allows Finite Resources to quickly adapt to emerging trends and meet the growing demand for gene therapies in the UK. 

Additionally, their focus on developing targeted therapies brings forth a unique strength that appeals to patients and healthcare systems seeking efficient solutions. The adaptability and agility of Finite Resources in navigating regulatory landscapes and market dynamics further solidify its competitive standing in the rapidly evolving gene therapy space.Amgen, a significant player in the UK Gene Therapy Market, has a robust portfolio of innovative products and services aimed at addressing unmet medical needs. The company is actively involved in the development and commercialization of gene therapies that target various genetic conditions, leveraging its advanced research capabilities and extensive clinical experience. 

Key products have begun to emerge as transformative treatments, and Amgen’s ongoing commitment to research and development fosters a culture of innovation. The company's market presence is augmented by strategic mergers and acquisitions that enhance its technological capabilities and expand its therapeutic offerings in the UK. Amgen’s strong financial position allows for substantial investments in clinical trials and collaborations, further strengthening its competitive advantage in the gene therapy domain, ensuring they remain at the forefront of this revolutionary market.

**Key Companies in the UK Gene Therapy Market Include**

**UK Gene Therapy Market Industry Developments**

The UK Gene Therapy Market is experiencing significant advancements, underscored by recent developments in various companies. Finite Resources, Amgen, and GSK are exploring innovative gene therapies to treat genetic disorders, while Bluebird Bio is progressing with trials for its gene editing technologies. In August 2023, Pfizer announced a strategic collaboration with uniQure, aimed at developing gene therapies targeting rare diseases, enhancing their position in the UK market. Furthermore, AstraZeneca remains committed to its gene therapy initiatives, with plans to expand Research and Development efforts in the UK. 

The gene therapy sector is projected to see substantial valuation growth, influenced by advancements in technology and increased government support for biotechnology initiatives, reflecting the UK's strategic prioritization of healthcare innovation. Notably, in 2022, Roche completed its acquisition of Spark Therapeutics, further consolidating the gene therapy landscape in the UK. The last two to three years have seen a surge in investment and research activities, with financial backing from both private and public sectors bolstering major players like Bristol Myers Squibb, Novartis, and Celgene in their gene therapy endeavors.

**UK Gene Therapy Market Segmentation Insights**

**Gene Therapy Market Therapeutic Area****Outlook**

**Gene Therapy Market Technology****Outlook**

**Gene Therapy Market Application****Outlook**

**Gene Therapy Market Route of Administration****Outlook**

## Market Drivers

### Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders in the UK is a primary driver for the gene therapy market. Conditions such as cystic fibrosis, hemophilia, and muscular dystrophy are becoming more prevalent, necessitating innovative treatment options. According to recent estimates, approximately 1 in 25 individuals in the UK is affected by a genetic disorder, highlighting the urgent need for effective therapies. This growing patient population is likely to propel demand for gene therapies, as they offer the potential for long-term solutions rather than symptomatic treatments. The gene therapy market is thus positioned to expand significantly, as healthcare providers and patients alike seek advanced therapeutic options that address the root causes of these disorders.

### Supportive Government Policies and Funding

The UK government has been actively promoting the development of the gene therapy market through supportive policies and funding initiatives. Programs aimed at fostering innovation in biotechnology and healthcare are encouraging research and development in gene therapies. For instance, the UK government allocated £1.5 billion to support life sciences research, which includes gene therapy projects. This financial backing is likely to stimulate growth in the gene therapy market, as it provides the necessary resources for companies to advance their research and bring new therapies to market. The collaboration between public and private sectors is expected to enhance the overall ecosystem for gene therapy development.

### Technological Advancements in Gene Editing

Technological innovations in gene editing techniques, such as CRISPR-Cas9 and TALENs, are transforming the landscape of the gene therapy market. These advancements enable precise modifications to genetic material, enhancing the efficacy and safety of gene therapies. In the UK, research institutions and biotech companies are increasingly adopting these technologies, leading to a surge in clinical trials and product development. The gene therapy market is witnessing a shift towards more targeted therapies, which could potentially reduce treatment costs and improve patient outcomes. As these technologies continue to evolve, they are expected to drive further investment and interest in gene therapy solutions.

### Growing Awareness and Acceptance of Gene Therapies

There is a notable increase in public awareness and acceptance of gene therapies in the UK, which is positively influencing the gene therapy market. Educational campaigns and success stories from clinical trials are helping to demystify these advanced treatments. As patients and healthcare professionals become more informed about the potential benefits of gene therapies, the demand for these innovative solutions is likely to rise. The gene therapy market is benefiting from this shift in perception, as more individuals seek out these therapies for conditions previously deemed untreatable. This growing acceptance may lead to increased investment and research in the field.

### Expansion of Clinical Trials and Research Collaborations

The expansion of clinical trials and research collaborations in the UK is a significant driver for the gene therapy market. Numerous academic institutions and biotech companies are partnering to explore new gene therapy applications, resulting in a robust pipeline of potential treatments. The UK has become a hub for clinical research, with over 200 ongoing gene therapy trials reported in recent years. This collaborative environment fosters innovation and accelerates the development of new therapies, thereby enhancing the gene therapy market. As more successful trials emerge, they are likely to attract further investment and interest from stakeholders, contributing to the overall growth of the market.

## Future Outlook

The [Gene Therapy Market](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) is projected to grow at a 19.04% CAGR from 2025 to 2035, driven by advancements in technology, regulatory support, and increasing disease prevalence.

**New opportunities:**

- Development of personalized gene therapies for rare diseases
- Expansion of telehealth platforms for remote patient monitoring
- Investment in scalable manufacturing technologies for cost reduction

By 2035, the gene therapy market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Vector Type: Viral Vector (Largest) vs. Non-Viral Vector (Fastest-Growing)

In the UK gene therapy market, the distribution of market share between viral and non-viral vectors shows a clear dominance of viral vectors, which are widely recognized for their efficiency in delivering genetic material into target cells. This segment holds a significant share owing to established methodologies and successful product launches. Conversely, non-viral vectors, while currently holding a smaller share, have garnered interest due to their safety profile and ease of manufacture, contributing to their growing presence in the market.

Growth trends indicate that while viral vectors remain the cornerstone of gene therapy applications, non-viral vectors are poised for rapid advancement, attributed to rising research and development initiatives and increasing investments focused on novel delivery systems. The demand for safer therapeutic options without the risks associated with viral vectors has driven interest and innovation in the non-viral segment, marking it as an emerging leader in future gene therapy solutions.

Viral Vector (Dominant) vs. Non-Viral Vector (Emerging)

Viral vectors are characterized by their ability to efficiently deliver genetic material into cells, leveraging naturally occurring viral mechanisms for effective gene transfer. This dominance in the UK gene therapy market is fueled by a robust pipeline of viral vector-based therapies that have shown promise in clinical applications. In contrast, non-viral vectors, which include plasmid DNA, liposomes, and nanoparticles, are emerging as viable alternatives due to their favorable safety profile and scalability in manufacturing processes. The shift towards non-viral approaches is being driven by advancements in technology and a growing body of research emphasizing their potential to treat a wider range of genetic disorders with reduced immunogenicity.

### By Gene Type: Antigen (Largest) vs. Cytokine (Fastest-Growing)

In the UK gene therapy market, the gene type segment reveals a diversified landscape with Antigen holding a significant market share due to its extensive application in immunotherapy. Cytokine follows closely, showcasing promising growth potential driven by increasing research and development in regenerative medicine. Other noteworthy segments include Tumor Suppressor and Growth Factors, which also contribute to the overall market dynamics, albeit with smaller shares.

Growth trends in the gene type segment are largely influenced by advancements in technology and a deeper understanding of genetic diseases. The rapid development of personalized medicine and an increased focus on treating previously untreatable conditions are key drivers. Emerging therapies targeting Cytokines are particularly noteworthy, as they offer innovative solutions in the treatment landscape, enhancing patient outcomes and attracting substantial investment in R&D.

Antigen (Dominant) vs. Cytokine (Emerging)

Antigen represents a dominant force in the UK gene therapy market, primarily due to its central role in immunotherapeutic applications. It benefits from a well-established infrastructure and extensive clinical research that supports its efficacy in treating various diseases. Conversely, Cytokine is emerging as a new frontier in this market, leveraging cutting-edge technologies to harness the immune system's potential. The increasing prevalence of chronic diseases is propelling interest in Cytokine therapies, allowing for breakthrough developments. Both segments are crucial, with Antigen providing stability while Cytokine captures the innovative edge of the market, leading to a dynamic interplay between established methods and novel solutions.

### By Application: Oncological Disorders (Largest) vs. Rare Diseases (Fastest-Growing)

In the UK gene therapy market, the application segments display a varied distribution of market share. Oncological disorders have emerged as the largest segment, capturing a significant portion of the market due to the increasing prevalence of cancer and the heightened focus on developing targeted therapies. Rare diseases also represent a crucial segment, driven by advancements in gene editing technologies and growing recognition of the need for specialized treatments.

The growth trends within this sector showcase a robust trajectory, especially for rare diseases, which are regarded as the fastest-growing segment. The increasing investment in research and development for gene therapies targeting rare genetic disorders is a key driver, alongside regulatory incentives aimed at expediting the approval process for these innovative treatments. As a result, the competition among companies in the UK gene therapy market intensifies, with a focus on harnessing unique technologies to address unmet medical needs.

Oncological Disorders (Dominant) vs. Infectious Diseases (Emerging)

Oncological disorders dominate the UK gene therapy market, supported by extensive research and advancements in treatment protocols. This segment attracts significant investments due to its established therapeutic frameworks and a strong pipeline of innovative products. In contrast, infectious diseases represent an emerging area within the market, gaining traction as researchers explore gene therapies to combat viral and bacterial pathogens. The growing need for efficient treatments against persistent infections amplifies interest in this segment. While oncological therapies benefit from robust infrastructure and historical precedence, the exploration of gene therapy applications in infectious diseases is fueled by continuous innovations in delivery systems and genetic modifications. Both segments are pivotal, yet their developmental trajectories differ substantially, reflecting the diverse applications of gene therapy.

### By Delivery Method: In Vivo Gene Therapy (Largest) vs. Ex Vivo Gene Therapy (Fastest-Growing)

In the UK gene therapy market, In Vivo Gene Therapy holds the largest market share among delivery methods, demonstrating considerable traction as gene therapy technologies advance. This segment's dominance can be attributed to its ability to deliver therapeutic genes directly into the patient's cells, leading to increased adoption rates and rising interest from both providers and recipients alike.

Conversely, Ex Vivo Gene Therapy is emerging as the fastest-growing segment, driven by innovations in cell processing and gene editing technologies. Factors such as personalized medicine trends, coupled with advancements in regulatory pathways, are propelling this segment forward, making it increasingly attractive for research and clinical applications in the UK gene therapy domain.

In Vivo Gene Therapy (Dominant) vs. Ex Vivo Gene Therapy (Emerging)

In Vivo Gene Therapy is recognized as the dominant delivery method, providing direct interventions in the body that enhance therapeutic effectiveness. It allows for targeted delivery and the potential for robust outcomes in treating genetic disorders. On the other hand, Ex Vivo Gene Therapy is an emerging method characterized by its innovative approach of modifying cells outside the body before reintroducing them. This technique offers higher precision and customization, making it appealing for patient-specific therapies. Together, these delivery methods are reshaping the landscape of gene therapy, each playing a crucial role in therapeutic advancements and market diversification.

## Competitive Benchmarking

The gene therapy market in the UK is currently characterized by a dynamic competitive landscape, driven by rapid advancements in technology and increasing investment in research and development. Key players such as Novartis (CH), Gilead Sciences (US), and AstraZeneca (GB) are strategically positioning themselves through innovation and partnerships. Novartis (CH) has focused on expanding its gene therapy portfolio, particularly in rare diseases, while Gilead Sciences (US) emphasizes its commitment to developing transformative therapies for serious conditions. AstraZeneca (GB) is leveraging its strong pipeline and collaborations to enhance its market presence, indicating a collective strategy among these companies to foster innovation and address unmet medical needs.The market structure appears moderately fragmented, with several players vying for dominance. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This trend is likely to intensify as firms seek to improve their competitive edge. The influence of major players is significant, as their strategic initiatives shape the overall market dynamics, fostering a competitive environment that encourages innovation and collaboration.

In October  Novartis (CH) announced a partnership with a leading UK research institution to develop next-generation gene therapies targeting genetic disorders. This collaboration is expected to accelerate the development of innovative treatments, showcasing Novartis's commitment to advancing gene therapy solutions. Such strategic alliances are crucial for enhancing research capabilities and expediting the delivery of therapies to patients.

In September  Gilead Sciences (US) launched a new gene therapy aimed at treating a rare genetic condition, marking a significant milestone in its product pipeline. This launch not only reinforces Gilead's position in the market but also highlights its focus on addressing niche therapeutic areas. The introduction of this therapy is anticipated to enhance patient outcomes and solidify Gilead's reputation as a leader in gene therapy innovation.

In August  AstraZeneca (GB) expanded its gene therapy research initiatives by acquiring a biotech firm specializing in CRISPR technology. This acquisition is likely to bolster AstraZeneca's capabilities in gene editing, positioning the company to leverage cutting-edge technologies in its therapeutic offerings. The integration of CRISPR technology could potentially lead to breakthroughs in treating genetic disorders, further enhancing AstraZeneca's competitive standing.

As of November  the gene therapy market is witnessing trends such as digitalization and AI integration, which are reshaping competitive strategies. Companies are increasingly forming strategic alliances to enhance their research and development capabilities, indicating a shift towards collaboration over competition. The focus is moving from price-based competition to innovation, technology, and supply chain reliability, suggesting that future differentiation will hinge on the ability to deliver advanced therapies efficiently and effectively.

## Recent News & Developments

The UK Gene Therapy Market is experiencing significant advancements, underscored by recent developments in various companies. Finite Resources, Amgen, and GSK are exploring innovative gene therapies to treat genetic disorders, while Bluebird Bio is progressing with trials for its gene editing technologies. In August 2023, Pfizer announced a strategic collaboration with uniQure, aimed at developing gene therapies targeting rare diseases, enhancing their position in the UK market. Furthermore, AstraZeneca remains committed to its gene therapy initiatives, with plans to expand Research and Development efforts in the UK. 

The gene therapy sector is projected to see substantial valuation growth, influenced by advancements in technology and increased government support for biotechnology initiatives, reflecting the UK's strategic prioritization of healthcare innovation. Notably, in 2022, Roche completed its acquisition of Spark Therapeutics, further consolidating the gene therapy landscape in the UK. The last two to three years have seen a surge in investment and research activities, with financial backing from both private and public sectors bolstering major players like Bristol Myers Squibb, Novartis, and Celgene in their gene therapy endeavors.

## Report Scope

| MARKET SIZE 2024 | 306.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 364.26(USD Million) |
| MARKET SIZE 2035 | 2082.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.04% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB) |
| Segments Covered | Vector Type, Gene Type, Application, Delivery Method |
| Key Market Opportunities | Advancements in gene editing technologies enhance treatment options in the gene therapy market. |
| Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the gene therapy market, enhancing treatment accessibility and efficacy. |
| Countries Covered | UK |

## Frequently Asked Questions

**Q: What was the market valuation of the UK gene therapy market in 2024?**
A: The market valuation was $306.0 Million in 2024.

**Q: What is the projected market valuation for the UK gene therapy market by 2035?**
A: The projected market valuation for 2035 is $2082.0 Million.

**Q: What is the expected CAGR for the UK gene therapy market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 19.04%.

**Q: Which companies are considered key players in the UK gene therapy market?**
A: Key players include Novartis, Gilead Sciences, Sangamo Therapeutics, Bluebird Bio, Spark Therapeutics, CRISPR Therapeutics, Bristol-Myers Squibb, Roche, and AstraZeneca.

**Q: What are the two main types of vectors used in gene therapy, and what were their valuations in 2024?**
A: In 2024, Viral Vector was valued at $200.0 Million, while Non-Viral Vector was valued at $106.0 Million.

**Q: What types of gene therapies are included in the market, and what were their valuations in 2024?**
A: In 2024, Antigen therapies were valued at $30.6 Million, Cytokine and Tumor Suppressor therapies at $61.2 Million each, and others varied from $0.0 to $208.2 Million.

**Q: What applications are driving the UK gene therapy market, and what were their valuations in 2024?**
A: In 2024, Rare Diseases had a valuation of $91.8 Million, while Oncological Disorders were valued at $61.2 Million.

**Q: What delivery methods are utilized in gene therapy, and what were their valuations in 2024?**
A: In 2024, In Vivo Gene Therapy was valued at $122.4 Million, and Ex Vivo Gene Therapy at $183.6 Million.

**Q: How does the UK gene therapy market compare to other regions?**
A: While specific regional comparisons are not provided, the UK market is poised for substantial growth, indicated by its projected valuation increase.

**Q: What factors contribute to the growth of the UK gene therapy market?**
A: Factors include advancements in technology, increasing prevalence of genetic disorders, and the presence of leading companies driving innovation.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-gene-therapy-market-53258*